Naomi Hunder

3.3k total citations · 2 hit papers
35 papers, 2.5k citations indexed

About

Naomi Hunder is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Naomi Hunder has authored 35 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Naomi Hunder's work include Lymphoma Diagnosis and Treatment (16 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Naomi Hunder is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Naomi Hunder collaborates with scholars based in United States, Italy and Poland. Naomi Hunder's co-authors include Cassian Yee, John A. Thompson, Deborah W. Hendricks, Achim A. Jungbluth, Jianhong Cao, Herschel Wallen, Sacha Gnjatic, Cornelia M. Weyand, Jörg J. Goronzy and Dirk Huebner and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Naomi Hunder

35 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

2008 704 citations Naomi Hunder, Herschel Wallen et al. New England Journal of Medicine profile →
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →

Peers

Countries citing papers authored by Naomi Hunder

Since Specialization

Citations

This map shows the geographic impact of Naomi Hunder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naomi Hunder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naomi Hunder more than expected).

Fields of papers citing papers by Naomi Hunder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naomi Hunder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naomi Hunder. The network helps show where Naomi Hunder may publish in the future.

Co-authorship network of co-authors of Naomi Hunder

This figure shows the co-authorship network connecting the top 25 collaborators of Naomi Hunder. A scholar is included among the top collaborators of Naomi Hunder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naomi Hunder. Naomi Hunder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors 2023 ·Cancer Research ·Justin Call, (unknown), Ian Anderson, Debra L. Richardson, Zhu Chen, (unknown), Naomi Hunder, Erika Hamilton	2
2	Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors. 2023 ·Journal of Clinical Oncology ·Justin Call, Douglas Orr, (unknown), Debra L. Richardson, Zhu Chen, (unknown), Naomi Hunder, Erika Hamilton	6
3	209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors 2021 ·Annals of Oncology ·Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Anthony W.H. Chan, Erika Hamilton, Sherene Loi, D-Y. Oh, Leisha A. Emens, Amita Patnaik, (unknown), Y.H. Park, Valerie Odegard, (unknown), Geundoo Jang, Céline Jacquemont, Naomi Hunder, Sarina A. Piha‐Paul	20
4	Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting 2018 ·Biology of Blood and Marrow Transplantation ·Auayporn Nademanee, Anna Sureda, Patrick J. Stiff, Jerzy Hołowiecki, Muneer H. Abidi, Naomi Hunder, (unknown), (unknown), (unknown), John Sweetenham	27
5	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse 2016 ·Biology of Blood and Marrow Transplantation ·John Sweetenham, Jan Walewski, (unknown), Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Pat Stiff, Simonetta Viviani, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, Anna Sureda, Dirk Huebner, Emily K. Larsen, Naomi Hunder, Craig H. Moskowitz	12
6	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2015 ·The Lancet ·Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski	477
7	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study 2014 ·Journal for ImmunoTherapy of Cancer ·Shailender Bhatia, Brendan D. Curti, Marc S. Ernstoff, Michael S. Gordon, Elisabeth I. Heath, Wilson H. Miller, Igor Puzanov, David I. Quinn, Thomas W. Flaig, (unknown), Kelly Byrnes-Blake, Jeremy A. Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza, John A. Thompson	46
8	The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma 2014 ·Blood ·Craig H. Moskowitz, (unknown), Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Emily K. Larsen, Naomi Hunder, Jan Walewski	11
9	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study. 2014 ·Journal of Clinical Oncology ·Stephen M. Ansell, Anas Younes, Joseph M. Connors, Andrea Gallamini, Won Seog Kim, Jonathan W. Friedberg, Tatyana Feldman, Graham P. Collins, Nancy L. Bartlett, Jingyuan Wang, (unknown), Jessica Sachs, Dirk Huebner, Naomi Hunder, John Radford	6
10	Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies 2013 ·Cancer Chemotherapy and Pharmacology ·Tae Hyung Han, (unknown), Ranjana H. Advani, R.B. Berryman, Scott E. Smith, Andres Forero‐Torres, Joseph D. Rosenblatt, Mitchell R. Smith, Jasmine Zain, Naomi Hunder, Andreas Engert	13
11	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study 2013 ·The Lancet Oncology ·Anas Younes, Joseph M. Connors, Steven I. Park, Michelle A. Fanale, Megan M. O’Meara, Naomi Hunder, Dirk Huebner, Stephen M. Ansell	201
12	A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders 2012 ·Clinical Cancer Research ·John M. Timmerman, John C. Byrd, David Andorsky, Reiko Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel	53
13	Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study 2012 ·Journal of Clinical Oncology ·Teresa M. Petrella, Richard Tozer, Karl Bélanger, Kerry J. Savage, Ralph Wong, Michael Smylie, Suzanne Kamel‐Reid, Victor A. Tron, Bingshu E. Chen, Naomi Hunder, Linda Hagerman, Wendy Walsh, Elizabeth A. Eisenhauer	95
14	Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results 2009 ·Journal of Clinical Oncology ·Shailender Bhatia, Elisabeth I. Heath, Igor Puzanov, Wilson H. Miller, Brendan D. Curti, Michael Gordon, Marc S. Ernstoff, Diana F. Hausman, Naomi Hunder, John A. Thompson	2
15	Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 breakdown → 2008 ·New England Journal of Medicine ·Naomi Hunder, Herschel Wallen, Jianhong Cao, Deborah W. Hendricks, (unknown), (unknown), Achim A. Jungbluth, Sacha Gnjatic, John A. Thompson, Cassian Yee	704
16	Recombinant IL-21 in combination with sorafenib: Preliminary results from a phase I/II study in patients with metastatic renal cell cancer 2007 ·Molecular Cancer Therapeutics ·Shailender Bhatia, Brendan D. Curti, Michael A. Gordon, David I. Quinn, Todd DeVries, Naomi Hunder, John F. Thompson	2
17	Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells 2005 ·Proceedings of the National Academy of Sciences ·Veronika Groh, (unknown), Daniel Cioca, Naomi Hunder, Wei Wang, Stanley R. Riddell, Cassian Yee, Thomas A. Spies	74
18	Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis 1996 ·Journal of Molecular Medicine ·Víctor M. Martínez‐Taboada, Naomi Hunder, Gene G. Hunder, Cornelia M. Weyand, Jörg J. Goronzy	59
19	Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. 1994 ·The Journal of Experimental Medicine ·Cornelia M. Weyand, J. Schönberger, (unknown), Naomi Hunder, K. C. Hicok, Jörg J. Goronzy	138
20	Hla–drb1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis 1994 ·Arthritis & Rheumatism ·Cornelia M. Weyand, Naomi Hunder, Kevin C. Hicok, Gene G. Hunder, Jörg J. Goronzy	141

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact